Dihydropyrimidine Dehydrogenase (DPD)

By Targets:	Dihydropyrimidine Dehydrogenase (DPD) (5) Biochemical Assay Reagents (2) DNA/RNA Synthesis (5) Endogenous Metabolite (7) Isotope-Labeled Compounds (5) Nucleoside Antimetabolite/Analog (2) Reference Standards (3)
By Research Areas:	Cancer (12) Infection (1) Metabolic Disease (6)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Nucleoside Analogs (1) Thymidine (1)

Targets Recommended:

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-W012926

Dihydrouracil 1 Publications Verification 5,6-Dihydrouracil	Endogenous Metabolite	Metabolic Disease
Dihydrouracil (5,6-Dihydrouracil), a metabolite of Uracil, can be used as a marker for identification of dihydropyrimidine dehydrogenase (DPD)-deficient .

HY-W010450

Thymine 1 Publications Verification	Endogenous Metabolite	Metabolic Disease Cancer
Thymine, one of the four bases of DNA, is a substrate for rat liver dihydropyrimidine dehydrogenase (DPD), with a K_m value of 2.2 μM, K_i of 24 μM (using 5-FU as the DPD substrate), and a specific activity of 0.68 nmol/min/mg .

HY-124062

TAS-114 3 Publications Verification	DNA/RNA Synthesis	Cancer
TAS-114 is an orally active dual dUTPase/dihydropyrimidine dehydrogenase (DPD) inhibitor, can improving the therapeutic efficacy of fluoropyrimidine .

HY-17469

Gimeracil 3 Publications Verification Gimestat	DNA/RNA Synthesis Dihydropyrimidine Dehydrogenase (DPD)	Cancer
Gimeracil, a component of an oral fluoropyrimidine derivative S-1, inhibits DNA DSB repair and is a potent inhibitor of DPYD (dihydropyrimidine dehydrogenase, DPD) .

HY-10533

Eniluracil 1 Publications Verification 5-Ethynyluracil; GW776C85	Biochemical Assay Reagents	Cancer
Eniluracil (5-Ethynyluracil) is an orally active **dihydropyrimidine dehydrogenase** (DPD) inhibitor. Eniluracil irreversibly inhibits *DPD*, increases the oral bioavailability of 5-fluorouracil to 100%, and facilitates the uniform absorption and toxicity of 5-fluorouracil. Eniluracil can be used in cancer research of combination with fluoropyrimidines (including 5-fluorouracil) . Eniluracil is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-W012926S1

Dihydrouracil-d4 5,6-Dihydrouracil-d₄	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
Dihydrouracil-d₄ is the deuterium labeled Dihydrouracil . Dihydrouracil (HY-W012926), a metabolite of Uracil, can be used as a marker for identification of dihydropyrimidine dehydrogenase (DPD)-deficient .

HY-134160

5,6-Dihydro-5-Fluorouracil 5-DHFU; 5-FluoroDihydropyrimidine-2,4-dione; 5-Fluorodihydrouracil	Nucleoside Antimetabolite/Analog	Cancer
5,6-Dihydro-5-Fluorouracil (5-DHFU; 5-Fluorodihydropyrimidine-2,4-dione) is the active metabolite of the thymidylate synthase inhibitor prodrug 5-fluorouracil (HY-90006), which is formed from 5-fluorouracil by dihydropyrimidine dehydrogenase (DPD). 5,6-Dihydro-5-Fluorouracil is cytotoxic to HaCaT keratinocytes (IC50=13.5 μM). Intravenous administration of 5,6-Dihydro-5-Fluorouracil (90 mg/kg/wk) in combination with 5-fluorouracil and the DPD inhibitor eniluracil (HY-10533) slows tumor growth in a rat colon cancer model.

HY-W001983

5-Iodouracil	Dihydropyrimidine Dehydrogenase (DPD)	Cancer
5-Iodouracil (Compound 4b) is an irreversible dihydropyrimidine dehydrogenase (DPD) inhibitor (IC₅₀=0.22 μM). 5-Iodouracil is promising for research of DPD-overexpressing solid tumors like non-small cell lung cancer (NSCLC) .

HY-W012926S

Dihydrouracil-13C4,15N2 5,6-Dihydrouracil-¹³C₄,¹⁵N₂	Endogenous Metabolite	Metabolic Disease
Dihydrouracil- ¹³C₄, ¹⁵N₂ is the ¹³C and ¹⁵N labeled Dihydrouracil . Dihydrouracil (5,6-Dihydrouracil), a metabolite of Uracil, can be used as a marker for identification of dihydropyrimidine dehydrogenase (DPD)-deficient .

HY-134160S

5,6-Dihydro-5-Fluorouracil-13C,15N2 5-DHFU-¹³C,¹⁵N₂; 5-FluoroDihydropyrimidine-2,4-dione-¹³C,¹⁵N₂; 5-Fluorodihydrouracil-¹³C,¹⁵N₂	Isotope-Labeled Compounds Nucleoside Antimetabolite/Analog	Cancer
5,6-Dihydro-5-Fluorouracil- ¹³C, ¹⁵N₂ (5-DHFU- ¹³C, ¹⁵N₂) is the ¹³C- and ¹⁵N-labeled labeled 5,6-Dihydro-5-Fluorouracil (HY-134160). 5,6-Dihydro-5-Fluorouracil (5-DHFU; 5-Fluorodihydropyrimidine-2,4-dione) is the active metabolite of the thymidylate synthase inhibitor prodrug 5-fluorouracil (HY-90006), which is formed from 5-fluorouracil by dihydropyrimidine dehydrogenase (DPD). 5,6-Dihydro-5-Fluorouracil is cytotoxic to HaCaT keratinocytes (IC₅₀=13.5 μM). Intravenous administration of 5,6-Dihydro-5-Fluorouracil (90 mg/kg/wk) in combination with 5-fluorouracil and the DPD inhibitor eniluracil (HY-10533) slows tumor growth in a rat colon cancer model.

HY-W012926R

Dihydrouracil (Standard) 5,6-Dihydrouracil (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease
Dihydrouracil (Standard) is the analytical standard of Dihydrouracil. This product is intended for research and analytical applications. Dihydrouracil (5,6-Dihydrouracil), a metabolite of Uracil, can be used as a marker for identification of dihydropyrimidine dehydrogenase (DPD)-deficient[1][2].

HY-17469R

Gimeracil (Standard) Gimestat (Standard)	DNA/RNA Synthesis Dihydropyrimidine Dehydrogenase (DPD) Reference Standards	Cancer
Gimeracil (Standard) is the analytical standard of Gimeracil. This product is intended for research and analytical applications. Gimeracil, a component of an oral fluoropyrimidine derivative S-1, inhibits DNA DSB repair and is a potent inhibitor of DPYD (dihydropyrimidine dehydrogenase, DPD) .

HY-W777340

Gimeracil-13C3 Gimestat-¹³C₃	Isotope-Labeled Compounds DNA/RNA Synthesis Dihydropyrimidine Dehydrogenase (DPD)	Cancer
Gimeracil- ¹³C₃ (Gimestat- ¹³C₃) is the ¹³C-labeled Gimeracil (HY-17469). Gimeracil, a component of an oral fluoropyrimidine derivative S-1, inhibits DNA DSB repair and is a potent inhibitor of DPYD (dihydropyrimidine dehydrogenase, DPD) .

HY-17469S

Gimeracil-13C3,15N Gimestat-¹³C₃,¹⁵N	Isotope-Labeled Compounds	Cancer
Gimeracil- ¹³C₃, ¹⁵N (Gimestat- ¹³C₃, ¹⁵N) is ¹³C and ¹⁵N labeled Gimeracil. Gimeracil, a component of an oral fluoropyrimidine derivative S-1, inhibits DNA DSB repair and is a potent inhibitor of DPYD (dihydropyrimidine dehydrogenase, DPD) .

HY-W779020

Dihydrouracil-13C,15N2 5,6-Dihydrouracil-¹³C,¹⁵N₂	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
Dihydrouracil- ¹³C, ¹⁵N₂ (5,6-Dihydrouracil- ¹³C, ¹⁵N₂) is the ¹³C- and ¹⁵N-labeled Dihydrouracil (HY-W012926). Dihydrouracil (5,6-Dihydrouracil), a metabolite of Uracil, can be used as a marker for identification of dihydropyrimidine dehydrogenase (DPD)-deficient .

HY-W014109

(E)-5-(2-Bromovinyl)pyrimidine-2,4(1H,3H)-dione (E)-5-(2-Bromovinyl)uracil; BVU	DNA/RNA Synthesis	Infection
(E)-5-(2-Bromovinyl)uracil (BVU) is a pyrimidine base and an inactive metabolite of the antiviral agents sorivudine and (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) that may be regenerated to BVDU in vivo. BVU irreversibly inactivates dihydropyrimidine dehydrogenase (DPD) in an NADPH-dependent manner. It enhances the efficacy of the chemotherapeutic agent and DPD substrate 5-fluorouracil (HY-90006) in a P388 murine leukemia model when administered at a dose of 200 μmol/kg, increasing survival time.

HY-10533R

Eniluracil (Standard) 5-Ethynyluracil (Standard); GW776C85 (Standard)	Biochemical Assay Reagents Reference Standards	Cancer
Eniluracil (Standard) is the analytical standard of Eniluracil. This product is intended for research and analytical applications. Eniluracil (5-Ethynyluracil) is an orally active dihydropyrimidine dehydrogenase (DPD) inhibitor. Eniluracil irreversibly inhibits DPD, increases the oral bioavailability of 5-fluorouracil to 100%, and facilitates the uniform absorption and toxicity of 5-fluorouracil. Eniluracil can be used in cancer research of combination with fluoropyrimidines (including 5-fluorouracil) . Eniluracil is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-19413

Ro-09-4889	Dihydropyrimidine Dehydrogenase (DPD) Endogenous Metabolite	Cancer
Ro-09-4889 is a prodrug. Ro-09-4889 can inhibit dihydropyrimidine dehydrogenase (DPD) activity and its effect is dose-dependent. Ro-09-4889 can be used for cancer research .

Cat. No.	상품명	Category	Target	Chemical Structure

HY-W012926

Dihydrouracil 1 Publications Verification 5,6-Dihydrouracil	Natural Products Microorganisms Classification of Application Fields Disease markers Endocrine diseases Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Dihydrouracil (5,6-Dihydrouracil), a metabolite of Uracil, can be used as a marker for identification of dihydropyrimidine dehydrogenase (DPD)-deficient .

HY-W012926R

Dihydrouracil (Standard) 5,6-Dihydrouracil (Standard)	Structural Classification Natural Products Microorganisms Disease markers Endocrine diseases Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
Dihydrouracil (Standard) is the analytical standard of Dihydrouracil. This product is intended for research and analytical applications. Dihydrouracil (5,6-Dihydrouracil), a metabolite of Uracil, can be used as a marker for identification of dihydropyrimidine dehydrogenase (DPD)-deficient[1][2].

Cat. No.	상품명	Chemical Structure

HY-W012926S1

Dihydrouracil-d4
Dihydrouracil-d₄ is the deuterium labeled Dihydrouracil . Dihydrouracil (HY-W012926), a metabolite of Uracil, can be used as a marker for identification of dihydropyrimidine dehydrogenase (DPD)-deficient .

HY-W012926S

Dihydrouracil-13C4,15N2
Dihydrouracil- ¹³C₄, ¹⁵N₂ is the ¹³C and ¹⁵N labeled Dihydrouracil . Dihydrouracil (5,6-Dihydrouracil), a metabolite of Uracil, can be used as a marker for identification of dihydropyrimidine dehydrogenase (DPD)-deficient .

HY-134160S

5,6-Dihydro-5-Fluorouracil-13C,15N2
5,6-Dihydro-5-Fluorouracil- ¹³C, ¹⁵N₂ (5-DHFU- ¹³C, ¹⁵N₂) is the ¹³C- and ¹⁵N-labeled labeled 5,6-Dihydro-5-Fluorouracil (HY-134160). 5,6-Dihydro-5-Fluorouracil (5-DHFU; 5-Fluorodihydropyrimidine-2,4-dione) is the active metabolite of the thymidylate synthase inhibitor prodrug 5-fluorouracil (HY-90006), which is formed from 5-fluorouracil by dihydropyrimidine dehydrogenase (DPD). 5,6-Dihydro-5-Fluorouracil is cytotoxic to HaCaT keratinocytes (IC₅₀=13.5 μM). Intravenous administration of 5,6-Dihydro-5-Fluorouracil (90 mg/kg/wk) in combination with 5-fluorouracil and the DPD inhibitor eniluracil (HY-10533) slows tumor growth in a rat colon cancer model.

5,6-Dihydro-5-Fluorouracil-13C,15N2

5,6-Dihydro-5-Fluorouracil- ¹³C, ¹⁵N₂ (5-DHFU- ¹³C, ¹⁵N₂) is the ¹³C- and ¹⁵N-labeled labeled 5,6-Dihydro-5-Fluorouracil (HY-134160). 5,6-Dihydro-5-Fluorouracil (5-DHFU; 5-Fluorodihydropyrimidine-2,4-dione) is the active metabolite of the thymidylate synthase inhibitor prodrug 5-fluorouracil (HY-90006), which is formed from 5-fluorouracil by dihydropyrimidine dehydrogenase (DPD). 5,6-Dihydro-5-Fluorouracil is cytotoxic to HaCaT keratinocytes (IC₅₀=13.5 μM). Intravenous administration of 5,6-Dihydro-5-Fluorouracil (90 mg/kg/wk) in combination with 5-fluorouracil and the DPD inhibitor eniluracil (HY-10533) slows tumor growth in a rat colon cancer model.

HY-W777340

Gimeracil-13C3
Gimeracil- ¹³C₃ (Gimestat- ¹³C₃) is the ¹³C-labeled Gimeracil (HY-17469). Gimeracil, a component of an oral fluoropyrimidine derivative S-1, inhibits DNA DSB repair and is a potent inhibitor of DPYD (dihydropyrimidine dehydrogenase, DPD) .

HY-17469S

Gimeracil-13C3,15N
Gimeracil- ¹³C₃, ¹⁵N (Gimestat- ¹³C₃, ¹⁵N) is ¹³C and ¹⁵N labeled Gimeracil. Gimeracil, a component of an oral fluoropyrimidine derivative S-1, inhibits DNA DSB repair and is a potent inhibitor of DPYD (dihydropyrimidine dehydrogenase, DPD) .

HY-W779020

Dihydrouracil-13C,15N2
Dihydrouracil- ¹³C, ¹⁵N₂ (5,6-Dihydrouracil- ¹³C, ¹⁵N₂) is the ¹³C- and ¹⁵N-labeled Dihydrouracil (HY-W012926). Dihydrouracil (5,6-Dihydrouracil), a metabolite of Uracil, can be used as a marker for identification of dihydropyrimidine dehydrogenase (DPD)-deficient .

Cat. No.	Compare	상품명	Application	Reactivity	Image

HY-P82255

	DPD Antibody (YA2000) DPYD; Dihydropyrimidine Dehydrogenase [NADP(+)]; DHPDHase; DPD; Dihydrothymine Dehydrogenase; Dihydrouracil Dehydrogenase	WB, IHC-P, ICC/IF, FC	Human
	DPD Antibody (YA2000) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to DPD.

Compare Products


Products	해외재고보유 - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / 해외재고보유 - + 장바구니에 담기 견적 받기

Cat. No.	상품명		Classification

HY-10533

Eniluracil 1 Publications Verification 5-Ethynyluracil; GW776C85		Alkynes
Eniluracil (5-Ethynyluracil) is an orally active **dihydropyrimidine dehydrogenase** (DPD) inhibitor. Eniluracil irreversibly inhibits *DPD*, increases the oral bioavailability of 5-fluorouracil to 100%, and facilitates the uniform absorption and toxicity of 5-fluorouracil. Eniluracil can be used in cancer research of combination with fluoropyrimidines (including 5-fluorouracil) . Eniluracil is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Cat. No.	상품명		Classification

HY-W010450

Thymine 1 Publications Verification		Nucleoside Analogs Thymidine
Thymine, one of the four bases of DNA, is a substrate for rat liver dihydropyrimidine dehydrogenase (DPD), with a K_m value of 2.2 μM, K_i of 24 μM (using 5-FU as the DPD substrate), and a specific activity of 0.68 nmol/min/mg .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
호칭			Country or Region *
고객명 *			회사명 *
Department *
메일주소 *			상품명 *
Cat. No.			Requested quantity *
전화번호 *
비고

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides